세계의 mRNA 합성 원료 시장(2024-2028년)

The mRNA synthesis raw material market is forecasted to grow by USD 776.45 mn during 2023-2028, accelerating at a CAGR of 4.93% during the forecast period. The report on the mRNA synthesis raw material market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of chronic and infectious diseases, advancements in mRNA technology, and the advantages of mRNA vaccines.

Technavio's MRNA synthesis raw material market is segmented as below:

By Application

• Vaccine production
• Therapeutics production
• Others

By End-user

• Biopharmaceutical and pharmaceutical companies
• CROs and CMOs
• Academic and research institutions

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the collaborations in biotechnology and manufacturing processes related to mRNA synthesis as one of the prime reasons driving the mRNA synthesis raw material market growth during the next few years. Also, growing demand for sustainable and environmentally friendly raw materials and increasing R and D investments by pharmaceutical and biopharmaceutical companies will lead to sizable demand in the market.

The report on the MRNA synthesis raw material market covers the following areas:

• mRNA synthesis raw material market sizing
• mRNA synthesis raw material market forecast
• mRNA synthesis raw material market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading mRNA synthesis raw material market vendors that include Bayer AG, BioNTech SE, BOCSCI Inc., CELONIC Group, Corden Pharma International GmbH, Creative Biolabs, CureVac AG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, HONGENE, Jena Bioscience GmbH, Lonza Group Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, New England Biolabs Inc., Pfizer Inc., Promega Corp., Samsung Electronics Co. Ltd., Thermo Fisher Scientific Inc., and Yeasen Biotechnology Co. Ltd.. Also, the mRNA synthesis raw material market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global mRNA synthesis raw material market 2018 - 2022
• 4.2 Application Segment Analysis 2018 - 2022
• 4.3 End-user Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Application

• 6.1 Market segments
• 6.2 Comparison by Application
• 6.3 Vaccine production - Market size and forecast 2023-2028
• 6.4 Therapeutics production - Market size and forecast 2023-2028
• 6.5 Others - Market size and forecast 2023-2028
• 6.6 Market opportunity by Application

7 Market Segmentation by End-user

• 7.1 Market segments
• 7.2 Comparison by End-user
• 7.3 Biopharmaceutical and pharmaceutical companies - Market size and forecast 2023-2028
• 7.4 CROs and CMOs - Market size and forecast 2023-2028
• 7.5 Academic and research institutions - Market size and forecast 2023-2028
• 7.6 Market opportunity by End-user

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 China - Market size and forecast 2023-2028
• 9.9 Germany - Market size and forecast 2023-2028
• 9.10 UK - Market size and forecast 2023-2028
• 9.11 Japan - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 BioNTech SE
• 12.4 BOCSCI Inc.
• 12.5 Creative Biolabs
• 12.6 CureVac AG
• 12.7 F. Hoffmann La Roche Ltd.
• 12.8 HONGENE
• 12.9 Jena Bioscience GmbH
• 12.10 Lonza Group Ltd.
• 12.11 Maravai LifeSciences Holdings Inc.
• 12.12 Merck KGaA
• 12.13 New England Biolabs Inc.
• 12.14 Pfizer Inc.
• 12.15 Promega Corp.
• 12.16 Thermo Fisher Scientific Inc.
• 12.17 Yeasen Biotechnology Co. Ltd.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations